Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.